Ondansetron Oral Solution |
Zofran solution |
Clinical Trial: Ondansetron Treatment for Alcoholism
This study has been completed.
|
Purpose
The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the treatment of alcohol dependent patients; b) investigate whether early versus late onset alcoholism predicts treatment outcome; and c) determine whether the early and late onset groups respond differently to treatment. Individuals will be "typed" into early onset and late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient treatment program.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Alcoholism | Drug: ondansetron (Zofran) | Phase II |
MedlinePlus related topics: Alcoholism
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Official Title: Pharmacological Treatment for Alcoholism
Study completion: April 2000
Eligibility
Ages Eligible for Study: 25 Years - 60 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Meet criteria for alcohol dependence.
- Subjects with early onset alcoholism must also have a diagnosis of antisocial personality disorder.
- Understand the requirements of the study and be able to complete the questionnaires and rating scales.
Exclusion Criteria:
- Current diagnosis of substance dependence or self-report of having used narcotics (opiates, cocaine, amphetamine-like substances, and hallucinogens) in the 30 day period prior to study.
- Positive urine drug screen test for narcotics, barbiturates, or benzodiazepines.
- Receiving current psychotropic medications.
- Current history of other psychiatric disorders excluding nicotine dependence.
- Hepatocellular disease.
- Pregnant females.
Location Information
Texas
Substance Abuse Research Center, University of Texas Health Science Center, Houston, Texas, 77030, United States
More Information
Record last reviewed: August 2002
Last Updated: October 13, 2004
Record first received: November 2, 1999
ClinicalTrials.gov Identifier: NCT00000443
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Ondansetron Oral Solution (Drug Digest)
- Zofran solution (Drug Digest)

Not Signed In -

